Genomic Health, Inc. Colon Cancer Test Meets Main Trial Goal

April 14 (Reuters) - Molecular diagnostics company Genomic Health Inc. said a validation study of a test that predicts the possibilities of recurrence of stage II colon cancer met the main trial goal.
MORE ON THIS TOPIC